SUBSCRIPTION AGREEMENTSubscription Agreement • October 18th, 2006 • Imvision Therapeutics Inc. • Pharmaceutical preparations • Nevada
NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
Service AgreementService Agreement • October 18th, 2006 • Imvision Therapeutics Inc. • Pharmaceutical preparations
ImVisioN runs its business on the premises of the current main office of DBVN. In return for remuneration, DBVN provides premises and staff infrastructure for this purpose within the framework described in the following, and can provide further services on request.
Amendment of Collaboration Agreement dated February 2006Collaboration Agreement • October 18th, 2006 • Imvision Therapeutics Inc. • Pharmaceutical preparations
This is to confirm the intent of Therapeomics Inc. and ImVisioN GmbH (the “Parties”) to amend their Collaboration Agreement (“Agreement”) dated February 2005.
Consultancy Agreement Between ImVisioN GmbH, located at Feodor-Lynen-Str. 5, 30625 Hannover,Consultancy Agreement • October 18th, 2006 • Imvision Therapeutics Inc. • Pharmaceutical preparations
WHEREAS, ImVisioN is a biotechnology company focused on the development of immuno-therapeutics based on its proprietary MAT (Modulary-Antigen-Transporter Molecules) technology platform to treat allergic diseases.
Consultancy Agreement Between ImVisioN GmbH, located at Feodor-Lynen-Str. 5, 30625 Hannover, GermanyConsultancy Agreement • October 18th, 2006 • Imvision Therapeutics Inc. • Pharmaceutical preparations
WHEREAS, ImVisioN is a biotechnology company focused on the development of immuno-therapeutics based on its proprietary MAT (Modular-Antigen-Transporter Molecules) technology platform to treat allergic diseases.
COLLABORATION AGREEMENT Development of a Proof-of-Concept Formulation of IVN201 between ImVisioN GmbH, Feodor Lynen Strasse 5, D-30625 Hannover, Germany (“IMVISION”) and Therapeomic Inc., Biozentrum, University of Basel, Klingenbergstrasse 70, CH-4056...Collaboration Agreement • October 18th, 2006 • Imvision Therapeutics Inc. • Pharmaceutical preparations
IMVISION is a biotechnology company based in Hannover, Germany, and focused on the development of novel immuntherapies based on its MAT (Modular-Antigen-Transporter) technology platform to treat allergic diseases, autoimmune diseases and (chronic) infectious diseases.
